Arvid Lindau
Arvid Lindau | |
---|---|
Born | 23 July 1892 Malmö, Sweden |
Died | 7 September 1958 Lund, Sweden |
Nationality | Swedish |
Occupation | Pathologist |
Known for | Describing von Hippel–Lindau disease |
Arvid Lindau (23 July 1892 – 7 September 1958) was a renowned Swedish pathologist best known for his work in describing von Hippel–Lindau disease, a rare genetic disorder characterized by the formation of tumors and cysts in different parts of the body.
Early Life and Education[edit | edit source]
Arvid Lindau was born in Malmö, Sweden. He pursued his medical education at the Lund University, where he developed a keen interest in pathology. Lindau completed his medical degree in 1920 and subsequently began his career in medical research.
Career and Research[edit | edit source]
Lindau's most significant contribution to medicine was his detailed study of hemangioblastomas of the central nervous system. In 1926, he published a seminal paper that described the association between these tumors and other visceral lesions, which later became known as von Hippel–Lindau disease. His work laid the foundation for understanding the genetic basis of this condition.
Lindau's research extended beyond von Hippel–Lindau disease. He was also involved in studies of other pathological conditions and contributed to the development of diagnostic techniques in pathology.
von Hippel–Lindau Disease[edit | edit source]
von Hippel–Lindau disease is a hereditary condition associated with tumors arising in multiple organs. It is caused by mutations in the VHL gene, which is a tumor suppressor gene. The disease is named after Arvid Lindau and Eugen von Hippel, who independently described different aspects of the condition.
Legacy[edit | edit source]
Arvid Lindau's work has had a lasting impact on the field of medical genetics and pathology. His contributions to the understanding of von Hippel–Lindau disease have been instrumental in the development of genetic testing and management strategies for affected individuals.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD